Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Candidate Pathways, Whole Genome Scans
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

Cancer Research 68, 1691-1696, March 15, 2008. doi: 10.1158/0008-5472.CAN-07-2372
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Zhang, G.
Right arrow Articles by Tsao, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, G.
Right arrow Articles by Tsao, H.

Molecular Biology, Pathobiology, and Genetics

EphA2 Is an Essential Mediator of UV Radiation–Induced Apoptosis

Guoqi Zhang1,2, Ching-Ni Njauw1, Jong Min Park1, Chie Naruse4, Masahide Asano4 and Hensin Tsao1,2,3

1 Wellman Center for Photomedicine, 2 Department of Dermatology, Harvard Medical School, and 3 MGH Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; and 4 Division of Transgenic Animal Science, Advanced Science Research Center, Kanazawa University, Kanazawa, Japan

Requests for reprints: Hensin Tsao, Department of Dermatology, Massachusetts General Hospital, Bartlett 622, 48 Blossom Street, Boston, MA 02114. Phone: 617-726-9569; Fax: 617-724-2745; E-mail: htsao{at}partners.org.

Key Words: EphA2 • UV • Apoptosis

One of the physiologic consequences of excessive UV radiation (UVR) exposure is apoptosis. This critical response serves to eliminate genetically injured cells and arises, in part, from activation of DNA damage and p53 signaling. Other contributory pathways, however, likely exist but have not been fully characterized. In a recent global screen of UVR response genes in melanocytes, we identified the receptor tyrosine kinase EPHA2. Using a combination of genetic and pharmacologic approaches, we set out to investigate the upstream regulation of EphA2 by UVR and the functional consequences of this effect. We found that the UVR-associated increase in EphA2 occurs in melanocytes, keratinocytes, and fibroblasts from both human and murine sources. More specifically, UVR effectively up-regulated EphA2 individually in p53-null, p63-null, and p73-null murine embryonic fibroblasts (MEF), suggesting that the p53 family of transcription factors is not essential for the observed effect. However, inhibition of mitogen-activated protein kinase (MAPK) signaling by U0126 and PD98059 significantly reduced the UVR response whereas overexpression of oncogenic NRAS led to an increase in EphA2. These results confirm that UVR induces EphA2 by a p53-independent, but MAPK-dependent, mechanism. In response to UV irradiation, Epha2–/– MEFs were highly resistant to UVR-mediated cytotoxicity and apoptosis whereas introduction of EphA2 into both wild-type and p53-null MEFs led to activation of an apoptotic program that can be blocked by caspase-8 inhibition. These functional findings suggest that EphA2 is in fact an essential p53-independent, caspase-8–dependent proapoptotic factor induced by UVR. [Cancer Res 2008;68(6):1691–6]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2008 by the American Association for Cancer Research.